Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, de Boer R, Bakker NAM, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M, van der Hage JA, Wouters MWJM, Pronk LM, Geukes Foppen MH, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. van den Berg JH, et al. Among authors: van der hage ja, van zon m, van buuren mm, van rooij n. J Immunother Cancer. 2020 Aug;8(2):e000848. doi: 10.1136/jitc-2020-000848. J Immunother Cancer. 2020. PMID: 32753545 Free PMC article. Clinical Trial.
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN. Kvistborg P, et al. Among authors: van buuren mm, van rooij n. Oncoimmunology. 2012 Jul 1;1(4):409-418. doi: 10.4161/onci.18851. Oncoimmunology. 2012. PMID: 22754759 Free PMC article.
Human cancer regression antigens.
Kvistborg P, van Buuren MM, Schumacher TN. Kvistborg P, et al. Among authors: van buuren mm. Curr Opin Immunol. 2013 Apr;25(2):284-90. doi: 10.1016/j.coi.2013.03.005. Epub 2013 Apr 6. Curr Opin Immunol. 2013. PMID: 23566921 Review.
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, Nieuwland M, Stratton MR, Kerkhoven RM, Kesmir C, Haanen JB, Kvistborg P, Schumacher TN. van Rooij N, et al. Among authors: van dijk lj, van buuren mm. J Clin Oncol. 2013 Nov 10;31(32):e439-42. doi: 10.1200/JCO.2012.47.7521. Epub 2013 Sep 16. J Clin Oncol. 2013. PMID: 24043743 Free PMC article. No abstract available.
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schumacher TN. Linnemann C, et al. Among authors: van der burg sh, van buuren mm. Nat Med. 2015 Jan;21(1):81-5. doi: 10.1038/nm.3773. Epub 2014 Dec 22. Nat Med. 2015. PMID: 25531942
Biomarkers in cancer immunotherapy.
Schumacher TN, Kesmir C, van Buuren MM. Schumacher TN, et al. Among authors: van buuren mm. Cancer Cell. 2015 Jan 12;27(1):12-4. doi: 10.1016/j.ccell.2014.12.004. Cancer Cell. 2015. PMID: 25584891 Free article.
Neoantigen landscape dynamics during human melanoma-T cell interactions.
Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH. Verdegaal EM, et al. Among authors: van der burg sh, van der minne ce, van buuren mm. Nature. 2016 Aug 4;536(7614):91-5. doi: 10.1038/nature18945. Epub 2016 Jun 27. Nature. 2016. PMID: 27350335
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM. Donia M, et al. Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27. Cancer Res. 2017. PMID: 28655789
35 results